256 related articles for article (PubMed ID: 15070604)
1. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up.
Francken AB; Shaw HM; Thompson JF; Soong SJ; Accortt NA; Azzola MF; Scolyer RA; Milton GW; McCarthy WH; Colman MH; McGovern VJ
Ann Surg Oncol; 2004 Apr; 11(4):426-33. PubMed ID: 15070604
[TBL] [Abstract][Full Text] [Related]
2. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center.
Azzola MF; Shaw HM; Thompson JF; Soong SJ; Scolyer RA; Watson GF; Colman MH; Zhang Y
Cancer; 2003 Mar; 97(6):1488-98. PubMed ID: 12627514
[TBL] [Abstract][Full Text] [Related]
3. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging.
Marghoob AA; Koenig K; Bittencourt FV; Kopf AW; Bart RS
Cancer; 2000 Feb; 88(3):589-95. PubMed ID: 10649252
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.
Clemente CG; Mihm MC; Bufalino R; Zurrida S; Collini P; Cascinelli N
Cancer; 1996 Apr; 77(7):1303-10. PubMed ID: 8608507
[TBL] [Abstract][Full Text] [Related]
5. Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry.
Eigentler TK; Buettner PG; Leiter U; Garbe C;
J Clin Oncol; 2004 Nov; 22(21):4376-83. PubMed ID: 15514379
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
8. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma.
Francken AB; Accortt NA; Shaw HM; Wiener M; Soong SJ; Hoekstra HJ; Thompson JF
Ann Surg Oncol; 2008 May; 15(5):1476-84. PubMed ID: 18196345
[TBL] [Abstract][Full Text] [Related]
9. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma.
Barnhill RL; Katzen J; Spatz A; Fine J; Berwick M
J Cutan Pathol; 2005 Apr; 32(4):268-73. PubMed ID: 15769275
[TBL] [Abstract][Full Text] [Related]
10. Mitotic rate in melanoma: a reexamination.
Attis MG; Vollmer RT
Am J Clin Pathol; 2007 Mar; 127(3):380-4. PubMed ID: 17276944
[TBL] [Abstract][Full Text] [Related]
11. The complex relationships between sentinel node positivity, patient age, and primary tumor desmoplasia: analysis of 2303 melanoma patients treated at a single center.
Sassen S; Shaw HM; Colman MH; Scolyer RA; Thompson JF
Ann Surg Oncol; 2008 Feb; 15(2):630-7. PubMed ID: 18080717
[TBL] [Abstract][Full Text] [Related]
12. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study.
Barnhill RL; Fine JA; Roush GC; Berwick M
Cancer; 1996 Aug; 78(3):427-32. PubMed ID: 8697387
[TBL] [Abstract][Full Text] [Related]
13. Thick cutaneous malignant melanoma: a reappraisal of prognostic factors.
Massi D; Borgognoni L; Franchi A; Martini L; Reali UM; Santucci M
Melanoma Res; 2000 Apr; 10(2):153-64. PubMed ID: 10803716
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society.
Leiter U; Buettner PG; Eigentler TK; Garbe C
J Clin Oncol; 2004 Sep; 22(18):3660-7. PubMed ID: 15302905
[TBL] [Abstract][Full Text] [Related]
15. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma.
Rossi CR; Mocellin S; Pasquali S; Pilati P; Nitti D
Ann Surg Oncol; 2008 Jan; 15(1):310-5. PubMed ID: 17987346
[TBL] [Abstract][Full Text] [Related]
16. Predicting ten-year survival of patients with primary cutaneous melanoma: corroboration of a prognostic model.
Sahin S; Rao B; Kopf AW; Lee E; Rigel DS; Nossa R; Rahman IJ; Wortzel H; Marghoob AA; Bart RS
Cancer; 1997 Oct; 80(8):1426-31. PubMed ID: 9338466
[TBL] [Abstract][Full Text] [Related]
17. Classification of localized melanoma by the exponential survival trees method.
Huang X; Soong S; McCarthy WH; Urist MM; Balch CM
Cancer; 1997 Mar; 79(6):1122-8. PubMed ID: 9070489
[TBL] [Abstract][Full Text] [Related]
18. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model.
Tuthill RJ; Unger JM; Liu PY; Flaherty LE; Sondak VK;
Am J Clin Pathol; 2002 Oct; 118(4):504-11. PubMed ID: 12375635
[TBL] [Abstract][Full Text] [Related]
19. Contemporary surgical treatment of advanced-stage melanoma.
Essner R; Lee JH; Wanek LA; Itakura H; Morton DL
Arch Surg; 2004 Sep; 139(9):961-6; discussion 966-7. PubMed ID: 15381613
[TBL] [Abstract][Full Text] [Related]
20. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas.
Gimotty PA; Elder DE; Fraker DL; Botbyl J; Sellers K; Elenitsas R; Ming ME; Schuchter L; Spitz FR; Czerniecki BJ; Guerry D
J Clin Oncol; 2007 Mar; 25(9):1129-34. PubMed ID: 17369575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]